Home Featured Page 2

Featured

Latest

Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on the GH-AtaiBeckley Patent Standoff; Field Reacts to FDA’s Guidance; Resilient Readies Resubmission

Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts

The Vital Conference: Breckenridge 2026

JOURNEYS: A Film Experience + Live Conversation with the Filmmakers

Psychedelic Policy Briefing: Week of July 20th, 2026

Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27...

Psychedelic Policy Briefing: Week of July 6, 2026

Psychedelics Today at the Aspen Psychedelic Symposium

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit...

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the...

Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on...

Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts

The Vital Conference: Breckenridge 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on the GH-AtaiBeckley Patent Standoff; Field Reacts to FDA’s Guidance; Resilient Readies Resubmission

Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts

The Vital Conference: Breckenridge 2026

JOURNEYS: A Film Experience + Live Conversation with the Filmmakers

Psychedelic Policy Briefing: Week of July 20th, 2026

Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27...

Psychedelic Policy Briefing: Week of July 6, 2026

Psychedelics Today at the Aspen Psychedelic Symposium

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit...

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the...

Psychedelics & Society

EDITOR PICKS

Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on...

Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts

The Vital Conference: Breckenridge 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY